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Summary
Background: Cyclosporine represents a mile-
stone in immunosuppression following organ
transplantation. Its use, however, comes at the cost
of significant side effects, such as arterial hyper-
tension which is rarely controllable by currently
available anti-hypertensive drugs. The aim was to
investigate the effect of acute administration of
nitroglycerin in heart-transplanted patients with
cyclosporine-induced hypertension.
Methods: The sample included 18 cy-
closporine-induced hypertensive patients (HTX
group) scheduled for elective cardiac catheteriza-
tion following heart transplantation, as well as
6-matched essential hypertensive patients (HT
group). The blood pressure (BP) in the aorta and
pulmonary artery, before and after administration
of nitroglycerin, was measured simultaneously.
Results:After injection of 50 mg and 100 mg ni-
troglycerin, BP significantly decreased both in
HTX (systolic [s] BP p = 0.0001; diastolic [d] BP
p = 0.0001) and in controls (sBP p = 0.006; dBP
p = 0.05).This reduction was more pronounced in
HTX (sBP p = 0.022; dBP p = 0.018 for group-
comparison). Following analysis of the data in re-
lation to its individual baseline, a significantly
higher reduction of the BP induced by 100 mg ni-
troglycerin was observed in the HTX group com-
pared to the HT group (p = 0.02 for sBP and p =
0.03 for dBP). 8 ± 3 minutes after the last nitrate
infusion, BP remained significantly reduced com-
pared to baseline in HTX (p <0.001), whereas it
came back to baseline in controls. The reduction
in sBP was correlated to cyclosporine A levels (p =
0.04 after 50 mg nitroglycerin; p = 0.05 after 100
mg nitroglycerin).
Conclusion: After application of nitroglycerin,
sBP is reduced immediately in HTX with uncon-
trolled cyclosporine-induced hypertension. Fur-
ther studies are needed to evaluate the long-term
effect of nitrates in these patients.
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Introduction
Cyclosporine A (CsA) is still the most com-
monly prescribed immunosuppressive drug fol-
lowing heart transplantation, however its use is
limited by side effects, particularly arterial hyper-
tension, deterioration of renal function, throm-
boembolic complications and graft atherosclerosis
[1–6].
CsA induces vasoconstriction in the systemic
circulation thereby increasing arterial blood pres-
sure (BP). Moreover, vasoconstriction in the kid-
ney vessels results in a decreased renal blood flow
and represents the pathophysiological basis for the
nephrotoxicity observed during CsA treatment.As
a consequence, many patients develop hyperten-
sion or exhibit deterioration of existing hyperten-
sion during immunosuppressive treatment. Un-
fortunately, the cyclosporine-induced hyperten-
sion is rarely controllable by currently available
anti-hypertensive drugs [7].
The precise mechanisms underlying cy-
closporine-induced hypertension still remain to
be elucidated [5], but cyclosporine-induced vaso-
constriction is believed to be due to an imbalance
of vasodilation (induced by prostacyclin, nitric
oxide, Ca
2+
influx) and vasoconstriction (due to
thromboxane, endothelin, angiotensin II, sympa-
thetic nervous system) [5, 8, 9].
CsA induces endothelial dysfunction in ani-
mal models [7, 10].Aortic rings dissected from rats
treated for several days with CsA show reduced
endothelium-dependent relaxation [11]. CsA in-
hibited the endothelial nitric oxide synthase activ-
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ity and reduced urinary nitrate/nitrite excretion in
vivo in rats, suggesting depressed nitric oxide
production [12–14]. In healthy volunteers, acute
administration of CsA enhances both basal and
receptor-stimulated nitric oxide activity [15],
while in heart transplanted (HTX) patients treat-
ment with CsA caused a reduction of basal and
stimulated release of nitric oxide [16], and a re-
duced flow mediated dilation [17] was found.
Moreover, in patients treated with CsA, endog-
enous vasodilators such as prostacyclin and nitric
oxide are suppressed, whereas vasoconstrictors, in-
cluding endothelin, are increased [8].
In experimental models of heart transplanta-
tion, cyclosporine also increases oxidative stress
[12] and influences production of important
pro-inflammatory mediators such as substances
showing a potential pro-fibrotic effect [18].
Nitrates are predominantly used for the treat-
ment of cardiovascular diseases including coro-
nary artery disease, and congestive heart failure
[19–23]. Their pronounced effect on vascular
smooth muscle and the release of nitric oxide are
believed to be key mechanisms of their anti-
ischemic properties [24–27]. Nitrates may have a
role in modifying the imbalance induced by CsA
throughmany different mechanisms, including in-
creasing nitric oxide, reducing angiotensin II and
endothelin, and modifying Ca
2+
influx.
This study was designed to investigate the po-
tential role of nitrates as a therapeutic strategy in
CsA-induced hypertension in HTX patients.
For this aim,we investigated the acute haemo-
dynamic effects of nitroglycerin (GTN) in HTX
patients with cyclosporine-induced hypertension
compared with a control group of essential hyper-
tensive patients (HT).
Methods
systolic (sBP) and diastolic blood pressure (dBP) and heart
rate (HR), by the haemodynamic monitoring system rou-
tinely used in our cardiac catheter laboratory (Schwarzer
evo, Schwarzer GmbH, Medical Equipment for Diagno-
sis,Munich,Germany), in the aorta and pulmonary artery
at baseline and within a minute following intracoronary
injection of 50 mg and 100 mg of GTN as bolus, respec-
tively.At the end of the angiographic examination, BP and
HR were measured again.
Blood sample
A blood sample for the analysis of the CsA trough
levels (in the HTX group only), total cholesterol, HDL
and LDL cholesterol, triglycerides, glucose, creatinine,
sodium, potassium and calcium was obtained at the day of
the coronary angiography.
Statistical analysis
Results are presented as mean ± SD. Changes in BP
and HR before and after nitrate infusion were analyzed
with ANOVA for repeated measures, comparisons of
clinical data were made by 2-tailed paired or unpaired
t-test and, where appropriate, the relationship between
CsA levels and changes in BP and HR was analyzed by
simple regression (Stat View 4.5,Abacus Concepts, USA).
Statistical significance was accepted at p <0.05. Due to the
clinical indication for the examination, the interventional
cardiologist performing the examination was not blinded.
However, data analysis was performed by an investigator
blinded to the group (HTX/controls).
Patients
Eighteen hypertensiveHTXpatients on cyclosporine
therapy and 6 HT controls were included. All HTX pa-
tients had been treated with CsA since their heart trans-
plantation (mean treatment duration 11 ± 4.8 years). The
diagnosis of hypertension was made 2.5 ± 0.7 months
after the heart transplantation and after starting therapy
with cyclosporine. All patients received state of the art
treatment at the moment of inclusion in the study and
they did not discontinue drug intake prior to the invasive
procedure.
Six essential HT patients, without prior transplanta-
tion and scheduled for a diagnostic cardiac catheteriza-
tion, served as a control group. Patients with significant
coronary lesions, as well as patients receiving immuno-
suppressive drugs of any kind or nitrate derivatives were
excluded.
All patients signed an informed consent for an inva-
sive diagnostic procedure and agreed to undergo nitrate
injection for the study. The local ethics committee of the
University Hospital Zurich approved the study protocol
and all procedures were in accordance with institutional
guidelines.
Coronary angiography and effect of acute infusion
of nitrates
First, coronary angiography and left ventriculogra-
phy were performed. After reaching a stable steady
haemodynamic state, the effect of GTN was evaluated by
simultaneous continuous measurement of intra-arterial
Results
Patients
The clinical characteristics of the study popu-
lation are shown in table 1. Age, weight and car-
diovascular risk factors were not different between
groups. HTX patients showed a higher dBP
(p = 0.01) and HR (p = 0.04), while no significant
difference in sBP was found. None of the patients
included in the control group had significant cor-
onary stenosis and none required an interven-
tional procedure.
Renal failure was more severe inHTX patients
probably as a consequence of CsA treatment; he-
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patic function was similar in the two groups. The
medications used by the patients included in our
study are shown in table 2.
Acute effects of nitrate injection on BP
and heart rate
Within a minute following injection of 50 mg
and 100 mg GTN, both the HTX-group and the
control group showed a dose-dependent decrease
in BP (sBP p = 0.0001 for HTX and p = 0.006 for
controls; dBP p = 0.0001 for HTX and p = 0.05 for
controls). In the aorta, both sBP and dBP de-
creased more in the HTX patients group than in
the reference group (sBP p = 0.04, dBP p = 0.03,
for group comparison) (fig. 1). When the data
were analysed as percent change, compared to
baseline, it was observed that the BP reduction in-
duced by 100 mg nitroglycerin was significantly
higher in the HTX group compared to the HT
group (p 0.02 for sBP and p = 0.03 for dBP) while
the effect of 50 mg nitroglycerin was not signifi-
cantly different in the two groups.
At the end of the angiographic study (mean
duration after the last infusion of nitrates 8 ± 3
minutes), BP in controls returned to baseline,
while in HTX patients BP remained significantly
lower when compared to baseline (DsBP p = 0.022
HTX vs. controls; DdBP p = 0.018 HTX vs. con-
trols) (fig. 1).
The central pressures measured during coro-
nary angiography are listed in table 3.
After injection of GTN, systolic pulmonary
artery pressure (p = 0.001 in the HTX group and
p = 0.01 in controls) and diastolic pulmonary pres-
sure (p = 0.006 in the HTX group and p = 0.047 in
controls) decreased significantly in both groups.
However, the reduction in systolic and diastolic
pulmonary pressure was not significantly different
in the HTX group compared to controls (n.s. for
group comparison).
Table 1
Clinical characteris-
tics of the study
population.
HTx: Heart-trans-
planted patients;
sBP: systolic blood
pressure, dBP:
diastolic blood
pressure, LDL: low
density lipoprotein,
HDL: high density
lipoprotein,
Na
+
: plasma sodium,
K
+
: plasma potas-
sium, Ca
2+
: plasma
calcium. Data are
expressed as mean
± SD.
Creatinine clearance
was calculated
according to the
Cockcroft formula.
*p <0.05 controls
vs HTx patients.
HTX
N = 18
Controls
N = 6
p
Baseline characteristics
Gender:
Male (%) 78 100
Female (%) 22 0
Age (years) 44 ± 5 42 ± 6 0.27
BMI (kg/m
2
) 27 ± 3 25 ± 14 0.80
sBP (mm Hg) 148 ± 19 134 ± 16 0.11
dBP (mm Hg) 82 ± 13 69 ± 12* 0.04
Heart rate (min
–1
) 82 ± 7 74 ± 11* 0.14
Cardiovascular Risk Factors
Total cholesterol (mmol/l) 4.8 ± 0.9 4.3 ± 0.8 0.35
LDL (mmol/l) 1.2 ± 0.4 1.3 ± 0.4 0.86
HDL (mmol/l) 2.4 ± 0.9 2.5 ± 0.4 0.90
Triglyceride (mmol/l) 2.5 ± 1.7 1.5 ± 0.8 0.09
Smoker (%) 62 66.7
Diabetes mellitus (%) 24 –
Renal parameters
Creatinine (mmol/l) 184 ± 120 106 ± 30 0.01
Calculated clearance (ml/min) 56.7 ± 26 81.7 ± 25.6 0.05
Na
+
(mmol/l) 139 ± 3 141 ± 1.2 0.05
K
+
(mmol/l) 4.3 ± 0.9 3.8 ± 0.3 0.09
Ca
2+
(mmol/l) 2.2 ± 0.2 2.23
Table 2
Medication taken by
the patients recruited
into the study.
HTx: Heart-trans-
planted patients;
ACE: angiotensin
converting enzyme,
AT: angiotensin,
Ca
2+
: calcium.
Medication (in %) HTX
n = 18
Control
n = 6
Cyclosporine 100 0
ACE inhibitor/AT-receptor antagonist 77.6 66.7
Diuretic 22.2 33.3
Ca
2+
antagonist 38.9 –
Beta blocker 50 50
Statin 83.3 66.7
Glucocorticoid 38.9 –
Macrolide 5.6 –
Azathioprin/Mycophenolate mofetil 100 –
Rapamicine 11.1 –
A
B
HTX patients
Control group
100 µg nitroglycerin
50 µg nitroglycerin
s
B
P
(
m
m
H
g
)
*
†
*
*
†
*
HTX patients (n=18) Controls (n=6)
†
s
B
P
(
m
m
H
g
)
Figure 1
Delta systolic blood pressure (DsBP) in HTx patients and in
the HT group within a minute after administration of 50 mg
and 100 mg nitroglycerin (A) and during the recovery time
(8 ± 3 minutes after the last infusion of nitroglycerin) (B).
We found a treatment effect after nitroglycerin infusion
(p <0.001).This effect was true for both groups (p <0.01
for both groups), Interestingly, the HTx group showed a
significantly more pronounced effect on sBP (p = 0.038 for
group comparison). * p <0.05 or less vs baseline; † p <0.05
or less HTx vs controls. Data are expressed as mean ± SD.
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GTN injection increased HR in both HTX
patients and the control group. In the HTX
group, the increase in HR was maximal after 100
mg GTN, while in the control group the increase
already reached its maximum after 50 mg GTN
(fig. 2). No significant difference was found when
the percent changes in HR in the HTX and in the
control group were compared.
Table 3
Blood pressure at
baseline and following
nitroglycerin infusion.
Blood pressure values
measured in the aorta
and the pulmonary
artery during the
haemodynamic study
at baseline and
following nitroglycerin
infusion. Data are
expressed as mean ±
SD. HTx: Heart-trans-
planted patients;
SBP: systolic blood
pressure, DBP:
diastolic blood
pressure, MBP: mean
blood pressure,
SPP: systolic pulmo-
nary pressure, DPP:
diastolic pulmonary
pressure, MPP: mean
pulmonary pressure.
Data are expressed
as mean ± SD.
HTX (n 18) Control (n 6)
Baseline
SBP aorta (mm Hg) 148 ± 19.4 134 ± 15.7
DBP aorta (mm Hg) 82 ± 13.0 69 ± 11.6
MBP aorta (mm Hg) 104 ± 13.9 90 ± 10.4
SPP (mm Hg) 26 ± 7.8 32 ± 10.0
DPP (mm Hg) 13 ± 4.2 14 ± 8.2
MPP (mm Hg) 17 ± 5.3 20 ± 8.2
After 50 mg nitroglycerine
SBP aorta (mm Hg) 126 ± 14.2 117 ± 17.8
DBP aorta (mm Hg) 75 ± 12.9 64 ± 11.6
MBP aorta (mm Hg) 92 ± 12.6 82 ± 11.5
SPP (mm Hg) 23 ± 5.6 27 ± 10.1
DPP (mm Hg) 12 ± 4.5 14 ± 7.6
MPP (mm Hg) 15 ± 4.6 18 ± 8.1
After 100 mg <nitroglycerine
SBP aorta (mm Hg) 113 ± 16.1 113 ± 26.0
DBP aorta (mm Hg) 70 ± 11.7 63 ± 11.9
MBP aorta (mm Hg) 84 ± 12.3 79 ± 14.6
SPP (mm Hg) 21 ± 5.9 24 ± 7.8
DPP (mm Hg) 10 ± 4.4 14 ± 6.9
MPP (mm Hg) 14 ± 4.6 17 ± 7.0
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Figure 2
Changes in heart rate induced by nitroglycerin in heart-
transplanted patients and in the control hypertensive group.
Heart rate recorded in heart-transplanted (HTx) patients
and in the hypertensive control group at baseline, after
administration of 50 mg and 100 mg nitroglycerin and
during the recovery time (8 ± 3 minutes after the last
infusion of nitroglycerin). Data are expressed as mean ± SD.
Cyclosporine blood concentration and effect
of GTN
In the HTX group, a significant relationship
was found between the absolute (50 mg nitrate:
r: 0.57, p = 0.01; 100 mg nitrate: r: 0.48, p = 0.04)
and percentage (50 mg nitrate: r: 0.54, p = 0.02;
100 mg nitrate: r: 0.46, p = 0.05) decrease in sBP
with blood concentration of CsA. No correlation
was obtained between the changes in dBP or HR.
Similarly, no correlation was observed be-
tween baseline sBP and dBP and CsA levels, while
a significant correlation was found with HR
(r: 0.55, p = 0.02).
Discussion
In this study, it has been demonstrated that, in
HTX patients treated with cyclosporine, an acute
infusion of GTN on top of a standard antihyper-
tensive therapy may induce a further reduction in
BP. This reduction was significantly more pro-
nounced and long lasting than that induced in HT
patients enrolled as controls.Moreover, the reduc-
tion in sBP showed a significant correlation with
cyclosporine concentration.
HTX patients receiving CsA often develop ar-
terial hypertension that is unlikely to be treated,
even with an optimal association therapy [9]. In
animal models, nitrate showed the potential for
reducing cyclosporine-induced hypertension [28,
29]. Due to the difficulty in controlling cy-
closporine-induced hypertension, even when
treated with more antihypertensive drugs, the
HTX patients were characterized by higher dBP.
Moreover, HR was also significantly higher in the
HTX group.These data are in line with a previous
report in patients soon, and later, after heart trans-
plantation [30] and may be explained by the ad-
ministration of CsA and the cardiac denervation
following HTX, respectively.
An acute infusion of cyclosporine induces an
increase in peripheral vascular resistance [31] and
an increase in total peripheral vascular resistance
was described in paediatric renal transplant pa-
tients treated with cyclosporine [32].This increase
in peripheral vascular resistance may explain the
higher dBP found in the HTX group.
Donor-heart cardioectomy with subsequent
orthotopic transplantation creates both afferent
and efferent cardiac denervation. Cardiac efferent
innervation mediates sympathetic and vagal ner-
vous system effects on the heart. The absence of
vagally mediated influences causes donor HR at
rest to be higher [33]. Even if a partial sympathetic
reinnervation is observed, HTX patients are
usually characterized by high HR [34]. The
143
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cyclosporine-induced increase in sympathetic
nervous activity [35] may explain the correlation
found between resting HR and CsA concentra-
tions.
In patients with stable graft function after re-
nal transplantation, Weingart and colleagues [36]
showed that nitroglycerin spray may reduce mean
arterial BP as well as the increase in renal vascular
resistance induced by the treatment with CsA.
In this study, we observed a dose-dependent
decrease in aortic BP following GTN injection in
HTX patients treated with cyclosporine, as well as
in hypertensive controls. This effect was signifi-
cantly more pronounced and lasted longer in
HTX patients compared to controls. Moreover,
we observed a significant reduction of pulmonary
pressures in HTX patients and controls. There-
fore, we can speculate that the reduction we
showed in the pulmonary circulation could be ex-
plained by the direct vasodilation induced by
GTN,while in HTX patients the aortic BP reduc-
tion induced by GTN could be explained not only
by direct vasodilation but also by acting on specific
mechanisms of the cyclosporine-induced hyper-
tension.
Cyclosporine was shown to decrease endothe-
lial-dependent vasodilators and to increase en-
dothelin level in animal models and in humans [3,
7, 8, 10–14, 37–44].Whereas nitrates partly substi-
tute deficient endogenous nitric oxide [45], they
could shift the imbalance to vasodilation. More-
over, while endogenous nitric oxide may inhibit
endothelin-1 production [46],
the release of exog-
enous nitric oxide by nitrates could also lead to an
inhibition of this potent vasoconstrictor and
therefore have a role in reducing the vasoconstric-
tion associated with cyclosporine-induced hyper-
tension. Another mechanism leading to vasodila-
tion after acute administration of nitrate could be
an influence on Ca
2+
mobilization. Nitrates may
influence the Angiotensin-II induced Ca
2+
mobili-
zation in vascular smooth muscle cells by an in-
creased amount of Ca
2+
in Angiotensin-II sensitive
intracellular Ca
2+
stores [47], as well as by the ef-
fect of exogenous nitric oxide that may decrease
free Ca
2+
, inhibit Ca
2+
influx and therefore support
the relaxation of vascular smooth muscle [48].
Therefore, nitrates may counteract angi-
otensin II and endothelin-1 at the level of vascular
smooth muscle by reducing Ca
2+
inflow and facili-
tating the vasodilator effects of nitric oxide, and
these effects may be responsible for the observed
stronger and more prolonged aortic BP reduction
which we observed in the HTX patient group.
Last but not least, animal studies have shown
that cyclosporine induced a disequilibrium in
the NO/cyclic guanosine-3′,5′-monophosphate
(cGMP) system, which may contribute to the vas-
cular hyperreactivity [12]. In rats, nitrate therapy
may provide a valid choice to prevent this cy-
closporine-induced NO-cGMP decrease, without
a negative influence on the oxidative equilibrium
[28, 29].
We found a significant correlation between
sBP but not dBP changes and CsA concentration.
The effect of cyclosporine on BP is dose-depend-
ent. The lack of correlation between changes in
dBP and CsA concentration might be explained by
the fact that nitrates were added on a “state of the
art” able to normalize dBP but not sBP (table 1).
Baseline HR [49] and HR response to physi-
ological stimuli [50] are very important prognostic
factors in HTX patients.
In this study, we observed a progressive in-
crease in HR related to the increasing dose of
GTN. In the control group, the increase of HR
was maximal after the first dose of GTN (50 mg)
while after the infusion of 100 mg the HR de-
creased. Due to parasympathetic and sympathetic
denervation of the heart, cardiac transplant recipi-
ents have an elevated resting HR, and an attenu-
ated HR response and a delayed normalization of
HR after stimulation [51]. Functional sympathetic
reinnervation has been demonstrated in humans
[52–54], while most studies do not provide con-
sistent evidence for parasympathetic reinnervation
[55]. Therefore, it can be speculated that in the
HT patients the response to the higher dose of
GTN is the sum of the sympathetic and vagal
stimulation, while in the HTX patients the para-
sympathetic component is not present or slower.
Limitations
The number of the control subjects included
in the study is small but sufficient to assure a sta-
tistical power superior to 80%. Moreover, the BP
was measured in lying position, a condition that
may have led to an underestimation of the effect of
nitrate. Finally, we did not assess the individual
maximal response to nitroglycerin but just the
change in BP observed within the first minute af-
ter intracoronary infusion of each dose of nitro-
glycerin.
Conclusions
The organic nitrates, like GTN, have similar
mechanisms of action and exert their therapeutic
effects through their active metabolite, nitric ox-
ide. Some of the main functional alterations in-
duced by cyclosporine and leading to hyperten-
sion, might be compensated by nitric oxide do-
nors. Our results following acute administration
of GTN indicate that the cyclosporine-induced
hypertension can, potentially, be treated. The
chronic use of GTN is, however, limited by the
well-known tachyphylaxis. The chronic affect of
NO donors, others than nitrates (such as sildena-
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fil, valdenafil, and molsidomine), should be care-
fully evaluated in controlled clinical studies in pa-
tients with cyclosporine-induced hypertension.
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